135 related articles for article (PubMed ID: 14999363)
21. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
22. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
23. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
24. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Honda Y; Ushigome F; Koyabu N; Morimoto S; Shoyama Y; Uchiumi T; Kuwano M; Ohtani H; Sawada Y
Br J Pharmacol; 2004 Dec; 143(7):856-64. PubMed ID: 15504753
[TBL] [Abstract][Full Text] [Related]
25. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes.
Inaba T; Fischer NE; Riddick DS; Stewart DJ; Hidaka T
Toxicol Lett; 1997 Dec; 93(2-3):215-9. PubMed ID: 9486958
[TBL] [Abstract][Full Text] [Related]
26. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
27. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
Robertson SM; Davey RT; Voell J; Formentini E; Alfaro RM; Penzak SR
Curr Med Res Opin; 2008 Feb; 24(2):591-9. PubMed ID: 18205997
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
Takanaga H; Ohnishi A; Matsuo H; Sawada Y
Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
[TBL] [Abstract][Full Text] [Related]
29. New insights into drug absorption: studies with sirolimus.
Paine MF; Leung LY; Watkins PB
Ther Drug Monit; 2004 Oct; 26(5):463-7. PubMed ID: 15385826
[TBL] [Abstract][Full Text] [Related]
30. Interaction of ritonavir on tissue distribution of a [(14)c]L-valinamide, a potent human immunodeficiency virus-1 protease inhibitor, in rats using quantitative whole-body autoradiography.
Solon EG; Balani SK; Luo G; Yang TJ; Haines PJ; Wang L; Demond T; Diamond S; Christ DD; Gan LS; Lee FW
Drug Metab Dispos; 2002 Nov; 30(11):1164-9. PubMed ID: 12386120
[TBL] [Abstract][Full Text] [Related]
31. Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization.
Jain R; Majumdar S; Nashed Y; Pal D; Mitra AK
Mol Pharm; 2004; 1(4):290-9. PubMed ID: 15981588
[TBL] [Abstract][Full Text] [Related]
32. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism.
Fitzsimmons ME; Collins JM
Drug Metab Dispos; 1997 Feb; 25(2):256-66. PubMed ID: 9029057
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH
AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801
[TBL] [Abstract][Full Text] [Related]
34. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).
Gupta A; Zhang Y; Unadkat JD; Mao Q
J Pharmacol Exp Ther; 2004 Jul; 310(1):334-41. PubMed ID: 15007102
[TBL] [Abstract][Full Text] [Related]
35. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
36. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
37. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Polli JW; Jarrett JL; Studenberg SD; Humphreys JE; Dennis SW; Brouwer KR; Woolley JL
Pharm Res; 1999 Aug; 16(8):1206-12. PubMed ID: 10468021
[TBL] [Abstract][Full Text] [Related]
38. Comparative effects on intestinal absorption in situ by P-glycoprotein-modifying HIV protease inhibitors.
Richter M; Gyémánt N; Molnár J; Hilgeroth A
Pharm Res; 2004 Oct; 21(10):1862-6. PubMed ID: 15553233
[TBL] [Abstract][Full Text] [Related]
39. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.
Eagling VA; Wiltshire H; Whitcombe IW; Back DJ
Xenobiotica; 2002 Jan; 32(1):1-17. PubMed ID: 11824416
[TBL] [Abstract][Full Text] [Related]
40. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals.
Meaden ER; Hoggard PG; Newton P; Tjia JF; Aldam D; Cornforth D; Lloyd J; Williams I; Back DJ; Khoo SH
J Antimicrob Chemother; 2002 Oct; 50(4):583-8. PubMed ID: 12356805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
